Press Releases

Mar 23

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with

Read More
Mar 21

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

CHARLESTOWN, Mass. , March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo , President and Chief Executive Officer, will participate in the BMO Biopharma

Read More
Mar 07

Solid Biosciences to Present at Barclays Global Healthcare Conference

CHARLESTOWN, Mass. , March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo , President and Chief Executive Officer, will present at the Barclays Global

Read More
Feb 08

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

CHARLESTOWN, Mass. , Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo , President and Chief Executive Officer, will present at the SVB Securities Global

Read More
Jan 26

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duchenne muscular dystrophy - - White paper submitted to the

Read More
Jan 11

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Research collaboration to target severe form of genetic dilated cardiomyopathy Collaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac therapy Collaboration allows Phlox Therapeutics to leverage Solid Biosciences’ vector biology and manufacturing

Read More
Jan 10

Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases

– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection and transition manufacturing process to transient transfection for AVB-202 for Friedrich's Ataxia and

Read More
Jan 09

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

CHARLESTOWN, Mass. , Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer,

Read More
Jan 09

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer

CHARLESTOWN, Mass. , Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan , CFA, a seasoned industry professional, as Chief Financial

Read More
Jan 09

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo , President and Chief Executive Officer, will present at the 41st Annual J.P.

Read More

News & Events

Press Releases